DDInter852 DDInter1676
Halofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine. It appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste. Halofantrine has been shown to preferentially block open and inactivated HERG channels leading to some degree of cardiotoxicity.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Halofantrine {u} (Compound) resembles {v} (Compound) Lumefantrine
Halofantrine {u} (Compound) binds {v} (Gene) CYP2C8
Halofantrine {u} (Compound) upregulates {v} (Gene) HMOX1
Halofantrine {u} (Compound) downregulates {v} (Gene) CDC20
Halofantrine {u} (Compound) causes {v} (Side Effect) Gastrointestinal pain
Halofantrine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tolterodine
Halofantrine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Iodide I-131
Halofantrine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Thalidomide
Halofantrine {u} may lead to a major life threatening interaction when taken with {v} Dasatinib
Halofantrine {u} may lead to a major life threatening interaction when taken with {v} Amiodarone
Halofantrine (Compound) resembles Lumefantrine (Compound)
Halofantrine (Compound) binds CYP2C8 (Gene)
Halofantrine (Compound) upregulates HMOX1 (Gene)
Halofantrine (Compound) downregulates CDC20 (Gene)
Halofantrine (Compound) causes Gastrointestinal pain (Side Effect)
Halofantrine may cause a minor interaction that can limit clinical effects when taken with Tolterodine
Halofantrine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131
Halofantrine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Halofantrine may lead to a major life threatening interaction when taken with Dasatinib
Halofantrine may lead to a major life threatening interaction when taken with Amiodarone